PDS Biotech, a portfolio company of NetScientific, has announced updated survival data from a Phase 2 clinical trial of its triple combination therapy for advanced HPV16-positive cancer patients. The trial investigated the combination of PDS0101, PDS0301, and an investigational immune checkpoint inhibitor (ICI) in two groups of patients: ICI-naïve patients who had not responded to standard-of-care treatments, and ICI-resistant patients who had not responded to multiple prior treatments, including ICI therapy. The data showed that 75% of ICI-naïve patients were still alive at 36 months, with a median overall survival (OS) that has not yet been reached. In comparison, published data on standard-of-care ICIs typically report that 30-50% of these patients remain alive at 12 months, and less than 30% remain alive at 24 months. In the ICI-resistant group, the 12-month OS rate was 72% and the triple combination achieved a median OS of approximately 20 months. The historical median survival for ICI therapy in HPV-positive cancer ICI-resistant patients is reported to be 3.4 months. PDS Biotech will be finalizing the regulatory and clinical pathway for the triple combination therapy with OS as the primary endpoint.